You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
  1. Kalijn Bol1,
  2. Thomas van den Bosch2,
  3. Gerty Schreibelt1,
  4. Cornelis Punt3,
  5. Carl Figdor1,
  6. Dion Paridaens2 and
  7. Jolanda de Vries1
  1. Aff1 grid.461760.2RIMLS Radboudumc Nijmegen Netherlands
  2. Aff2 grid.414699.70000000100097699Rotterdam Eye Hospital Rotterdam Netherlands
  3. Aff3 grid.5650.60000000404654431Academic Medical Center Amsterdam Netherlands

https://doi.org/10.1186/2051-1426-3-S2-P127

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    The presence of monosomy 3 in the primary tumor is widely accepted as the most reliable prognostic parameter, identified in approximately 50% of patients with primary uveal melanoma [1]. Long term studies have shown a 3-year survival rate of 40% if monosomy 3 is present, whereas tumors with normal chromosome 3 status rarely give rise to metastatic disease and have a 90% 3-year survival rate [2]. Currently, there is no effective adjuvant treatment for the patients with early stage uveal melanoma at high risk for metastatic disease (monosomy 3). The development of uveal melanoma at an immune-privileged site, the eye, made it questionable if immunotherapy would be a suitable treatment modality. Nonetheless, in this open label Phase II study we investigated the immunological responses in high risk uveal melanoma patients, selected based on monosomy 3, to dendritic cell vaccination.

    Methods

    Twenty-three patients with a primary uveal melanoma with monosomy 3 were included in this trial. HLA-A*02:01 positive patients received vaccinations with autologous dendritic cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures are safety, immunological response, progression-free and overall survival. ClinicalTrials.gov Identifier: NCT00929019.

    Results

    Tumor-specific immune responses were induced with dendritic cell vaccination in the majority of patients. Patients with a tumor-specific immune response showed a significant longer median progression free and overall survival compared to patients without a detectable tumor-specific immune response after dendritic cell vaccination. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Updated data will be presented.

    Conclusions

    Dendritic cell vaccination is feasible and safe in high risk uveal melanoma patients. Despite development of uveal melanoma at an immune-privileged site, dendritic cell-based immunotherapy is potent to enhance the host's anti-tumor immunity against uveal melanoma and tumor-specific immune responses correlate with longer progression free and overall survival.

    References

    1. 1.↵
      1. Prescher G,
      2. Bornfeld N,
      3. Hirche H,
      4. Horsthemke B,
      5. Jockel KH,
      6. Becher R
      . Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:90101222–1225. doi:10.1016/S0140-6736(96)90736-9
      OpenUrlCrossRefPubMedWeb of Science
    2. 2.↵
      1. White VA,
      2. Chambers JD,
      3. Courtright PD,
      4. Chang WY,
      5. Horsman DE
      . Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83:2354–359. doi:10.1002/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.0.CO;2-R
      OpenUrlCrossRefPubMedWeb of Science